| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/19/2011 | CN101951941A Methods for inhibiting scarring |
| 01/19/2011 | CN101951940A Treatment of autoimmune disorders |
| 01/19/2011 | CN101951939A Pegylation by the dock and lock (DNL) technique |
| 01/19/2011 | CN101951938A Methods and compositions related to internalizing RGD peptides |
| 01/19/2011 | CN101951937A Method of stimulating the motility of the gastrointestinal system using ipamorelin |
| 01/19/2011 | CN101951936A Methods for prevention and treatment of acute renal injury |
| 01/19/2011 | CN101951935A Therapeutic agent for cerebral ischemic injury |
| 01/19/2011 | CN101951893A Pharmaceutical compositions comprising granules of purified microbial lipase and methods of preventing or treating digestive disorders |
| 01/19/2011 | CN101951888A Enhancement of the efficacy of therapeutic proteins |
| 01/19/2011 | CN101948842A Heterometrus spinifer poison antibacterial polypeptide gene and preparation method and application thereof |
| 01/19/2011 | CN101948841A Epitope sequences |
| 01/19/2011 | CN101948839A Antimicrobial peptide gene from pinctada fucata and application |
| 01/19/2011 | CN101948835A Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
| 01/19/2011 | CN101948543A Fusion protein and coding gene and application thereof |
| 01/19/2011 | CN101948528A Fibrinolytic activated protein from cantharis, preparation method and application thereof |
| 01/19/2011 | CN101948523A Artificial in-vitro preparation method of low molecular weight amyloid peptide oligomer and application |
| 01/19/2011 | CN101948512A Polypeptide WA8 for inhibiting type-2 shiga toxin activity and coding gene and application thereof |
| 01/19/2011 | CN101948507A Novel anti-cancer medicaments using NGR(NO2) as targeting carrier, preparation thereof and use thereof |
| 01/19/2011 | CN101947315A Application of Chinese medicinal bitter apricot seeds in lysozyme sodium alginate microspheres |
| 01/19/2011 | CN101947314A Novel aqua for treating beriberi and preparation process thereof |
| 01/19/2011 | CN101947313A Novel effervescent tablet for treating beriberi and preparation process thereof |
| 01/19/2011 | CN101947312A Modified polyethylene glycol superoxide dismutase (mPEG-SOD) nanoemulsion capable of being directly externally used for skin and preparation method thereof |
| 01/19/2011 | CN101947311A Plasma substitute combination |
| 01/19/2011 | CN101947310A Adrenocorticotropic hormone analogs and related methods |
| 01/19/2011 | CN101947309A Human basic fibroblast growth factor eye drops and preparation method thereof |
| 01/19/2011 | CN101947308A Novel fish odinagogue |
| 01/19/2011 | CN101947307A Applications of human placenta peptide in preparing drugs for treating dry eye syndrome and other ocular surface diseases |
| 01/19/2011 | CN101947306A Treatment of T-cell mediated diseases |
| 01/19/2011 | CN101947213A Method for preparing microcapsules from peptidoglycan in lactic acid bacterial cell walls |
| 01/19/2011 | CN101947206A Method for preparing recombinant pancreotropic hormone secretion peptide medicament microspheres |
| 01/19/2011 | CN101224299B Preparing method of compounds capable of inducing tumor cell apoptosis |
| 01/19/2011 | CN101156947B Ginseng source peptide albumen, its preparing method and application |
| 01/19/2011 | CN101060856B Soluble, stable insulin-containing formulations with a protamine salt |
| 01/18/2011 | US7872114 Or Escherichia coli (E. coli) heat labile toxin where in the amino acid sequence, serine-63 and arginine-192 are replaced by another amino acid; vaccines against cholera and enterotoxigenic strain of E. coli |
| 01/18/2011 | US7872098 derivatives of peptide corresponding to the sequence RIHMVYSKRSGKPRGYAFIEY pharmaceutical compositions; capable of stimulating in vitro the proliferation and the secretion of IL-2 by the CD4+ T cells purified from the ganglia |
| 01/18/2011 | US7872096 ligating recombinant intein domains to a linear synthetic protein to form a compound D1-X(n)-D2, where D1 and D2 are catalytic domains of an intein and X is a protein; cell-free; producing small cyclic peptides containing non-genetically encodable amino acids; for drugs |
| 01/18/2011 | US7872094 using polypeptide comprising a membrane translocation domain and a NF- kappa B Essential Modulator (NEMO) binding sequence; comprising a NEMO binding domain (NBD) |
| 01/18/2011 | US7871998 Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
| 01/18/2011 | US7871997 Potency against gram-positive bacteria, methicillin-resistant Staphylococci aureus (MRSA), methicillin-resistant Staphylococci epidermitis (MRSE). |
| 01/18/2011 | US7871990 Nanoparticles for protein drug delivery |
| 01/18/2011 | US7871989 composed of chitosan, poly-glutamic acid, and a protein drug or bioactive agent characterized with a positive surface charge; enhanced permeability for paracellular protein drug and bioactive agent delivery via intravenous infusion or intramuscular injection with enhanced permeability; bioavailability |
| 01/18/2011 | US7871986 provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines |
| 01/18/2011 | US7871983 For therapy and prophylaxis of ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia |
| 01/18/2011 | US7871981 employing peptides, e.g., phosphotyrosine mimetics, to inhibit cell motility and angiogenesis; preventing and/or treating diseases, disorders, states, or conditions such as cancer, particularly metastatic cancer |
| 01/18/2011 | US7871980 increasing ratio of adult human hepatocytes to mouse hepatocytes in an immunodeficient hepatopathy mouse by transplanting adult human hepatocytes into the immunodeficient hepatopathy mouse and administering human growth hormone to the mouse |
| 01/18/2011 | US7871979 soluble colony stimulating factor 3 receptor (CSF3R) polypeptide variant; for graft-vs-host disease, cancer, neutropenia, neurological disorders, pneumonia, autoimmune, hematological and infectious diseases, inflammatory bowel disease, and diabetes |
| 01/18/2011 | US7871978 Administering a peptide, identified through a phage display library; osteogenesis, cell adhesion/angiogenesis, inhibiting cancer cell metastasis |
| 01/18/2011 | US7871977 Process for producing sterile suspensions of slightly soluble basic peptide complexes, sterile suspensions of slightly soluble basic peptide complexes, pharmaceutical formulations containing them, and the use thereof as medicaments |
| 01/18/2011 | US7871800 Polypeptides having glucoamylase activity and polynucleotides encoding same |
| 01/18/2011 | US7871798 Mammalian cells that express VEGF-D polypeptides |
| 01/18/2011 | US7871786 Isolated nucleic acid encoding GEF-H1b polypeptide (Guanine nucleotide exchange factors); diagnosing abnormal cell proliferation and drug screening; measuring phosphorylation by p-21 activated kinase; antitumor agents, anticancer agents |
| 01/18/2011 | US7871767 Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic applications |
| 01/18/2011 | US7871766 Cosmetic and/or dermopharmaceutical preparations containing native proteins from the plant Argania spinosa |
| 01/18/2011 | US7871765 Composition having antitumor effect |
| 01/18/2011 | US7871631 Inhibit inflammation for long periods without accompanying serious side effects in the drug therapy to patients with inflammatory bowel syndrome |
| 01/18/2011 | US7871630 Locally administering to tumor antigen-releasing agent, tumor leukocyte attractant and tumor interferon-gamma (IFN-g), and second type 1 inflammatory response-(IR1-)promoting agent for tumor therapy |
| 01/18/2011 | US7871628 Peptide mimics of conserved gonococcal epitopes and methods and compositions using them |
| 01/18/2011 | US7871620 Immunoliposomes that optimize internationalization into target cells |
| 01/18/2011 | US7871617 Von Willebrand's factor (VWC); transforming growth factors, bone morphongenic proteins as cofactors; monoclonal antibodies for use in diagnosis and treatment of diabetes, hypertension, hyperglycemia and congestive heart failure |
| 01/18/2011 | US7871609 Supplements for pain management |
| 01/18/2011 | US7871608 Reversibly inactivated acidified plasmin |
| 01/18/2011 | US7871607 use to treat glycosaminoglycan associated pathologies such as eye disorders or tumors; sialated and pegylated forms of a recombinant soluble neutral active Hyaluronidase Glycoproteins to enhance stability and serum pharmacokinetics over natural slaughterhouse enzymes; transgenic animals; dosage forms |
| 01/18/2011 | US7871603 Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly |
| 01/18/2011 | CA2637795C Antagonists of interleukin-15 |
| 01/18/2011 | CA2576549C Stable pegylated interferon formulation |
| 01/18/2011 | CA2466642C Injectable depot composition |
| 01/18/2011 | CA2455145C Pregnancy-related serine protease |
| 01/18/2011 | CA2451504C A process for the isolation of a major harmful oxidant from cigarette smoke |
| 01/18/2011 | CA2425445C Tetrapeptide stimulating functional activity of hepatocytes, pharmacological substance on its basis and the method of its application |
| 01/18/2011 | CA2408501C Melphalan derivatives and their use as cancer chemotherapeutic drugs |
| 01/18/2011 | CA2408008C Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
| 01/18/2011 | CA2385444C Humanin, a polypeptide suppressing neuronal death |
| 01/18/2011 | CA2383737C Muc-1 derived peptides |
| 01/18/2011 | CA2368637C Topical treatment or prevention of ocular infections |
| 01/18/2011 | CA2338665C Peg-urate oxidase conjugates and use thereof |
| 01/18/2011 | CA2310534C Methods and compositions for treating primary and secondary tumors of the central nervous system (cns) |
| 01/18/2011 | CA2285935C An immunotolerant prothrombin complex preparation |
| 01/18/2011 | CA2212832C Thrombin preparation |
| 01/18/2011 | CA2191053C A fusion protein comprising a furin derivative or a derivative of a furin analogue and a heterlogous sequence |
| 01/18/2011 | CA2189055C Methods for modulating t cell responses by manipulating intracellular signal transduction |
| 01/13/2011 | WO2011006084A2 Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof |
| 01/13/2011 | WO2011006079A2 Ophthalmic formulations of reversed liquid crystalline phase materials and methods of using |
| 01/13/2011 | WO2011006072A2 Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia |
| 01/13/2011 | WO2011006070A2 Genetic association of polymorphisms in perilipin (plin) gene with resistance to weight loss |
| 01/13/2011 | WO2011006029A1 Artificial cell constructs for inducing immunological tolerance |
| 01/13/2011 | WO2011005968A1 Codon-optimized factor vi i i variants and synthetic liver-specific promoter |
| 01/13/2011 | WO2011005939A2 Long acting atrial natriuretic peptide (la-anp) and methods for use thereof |
| 01/13/2011 | WO2011005907A1 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis |
| 01/13/2011 | WO2011005611A1 Neuromedin u receptor agonists and uses thereof |
| 01/13/2011 | WO2011005593A2 Schistosomiasis vaccine compositions and methods of use |
| 01/13/2011 | WO2011005577A1 Zinc supplementation to increase responsiveness to metalloprotease therapy |
| 01/13/2011 | WO2011005525A2 Prodrug anti-cancer therapy |
| 01/13/2011 | WO2011005523A2 Galectin-immunoglobulin chimeric molecules |
| 01/13/2011 | WO2011005510A2 Peptide conjugates and uses thereof |
| 01/13/2011 | WO2011005406A2 Skin repair compositions comprising circadian gene activators and a synergistic combination of sirt1 gene activators |
| 01/13/2011 | WO2011005380A2 Arg-gly-asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same |
| 01/13/2011 | WO2011005298A2 Enhancement of bmp retention |
| 01/13/2011 | WO2011005219A1 Novel mdm2 binding peptides and uses thereof |
| 01/13/2011 | WO2011005113A1 Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition |
| 01/13/2011 | WO2011004843A1 Pharmaceutical composition for treatment of sirs or highly pathogenic influenza infection |